LivaNova (LIVN) Baird 2024 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Baird 2024 Global Healthcare Conference summary
21 Jan, 2026Leadership focus and organizational development
Emphasis on talent development, with key leadership appointments in cardiopulmonary and innovation roles.
Building a benchmark innovation team, including new leaders in R&D and business development.
Focus on culture, engagement, and alignment to strategy to drive execution.
Execution and growth drivers
Achieved six quarters of double-digit growth, driven by focused execution and supply chain improvements.
Market share gains in cardiopulmonary disposables due to competitor constraints and capacity expansion.
Pricing optimization and manufacturing excellence are key levers for sustaining growth.
Strategic outlook and future planning
Strategy centers on maximizing core growth (epilepsy and cardiopulmonary), expanding into adjacencies (depression, sleep apnea), and defining the next growth chapter.
A long-term plan through 2030 will be shared, with a three-year and longer-term chapter, and an analyst day planned for the first half of next year.
Aspiration to become a benchmark med tech company, with above-market growth, margin expansion, and EPS improvement as key metrics.
Latest events from LivaNova
- Raised 2026 revenue and EPS guidance after double-digit Q1 growth and key regulatory wins.LIVN
Q1 20266 May 2026 - Shareholders will vote on directors, executive pay, auditors, share authority, and ESG initiatives.LIVN
Proxy filing29 Apr 2026 - AGM to address director elections, compensation, auditor matters, and share capital authorities.LIVN
Proxy filing29 Apr 2026 - Double-digit 2025 growth and margin gains set stage for 6–7% revenue growth in 2026.LIVN
Q4 202525 Feb 2026 - Q2 revenue up 10% and adjusted EPS up, with raised 2024 guidance and strong segment growth.LIVN
Q2 20242 Feb 2026 - Twelve key resolutions were presented and 89% of voting rights were represented.LIVN
AGM 20241 Feb 2026 - Core growth, innovation in DTD/OSA, and margin expansion drive a multi-year growth outlook.LIVN
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Q3 2024 revenue up 11.2%, margins expand, and guidance raised on strong segment growth.LIVN
Q3 202417 Jan 2026 - OSA market entry and reimbursement gains drive growth, with profitability targeted by 2029.LIVN
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026